Clinical trial Archives

News and Trends 20 Jan 2023

DeuterOncology closes financing round to start lung cancer study

DeuterOncology, a clinical-stage drug development company, has closed €5.65 million ($6.1 million) series A financing, to start the phase I clinical study for its lead product DO-2, an improved MET kinase inhibitor currently being developed as a potential best-in-class targeted therapy for lung cancer. The financing included participation from historical investor Newton Biocapital and new […]

January 20, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 19 Jan 2023

Cloned maggot enzyme wound treatment moves closer to reality

Cambridge U.K. biotech company SolasCure, which is developing a wound cleaning technology, has published its pre-clinical results with the International Wound Journal, showing preliminary evidence that supports its new enzymatic debridement product for use in chronic wounds. Debridement, the removal of all infected and nonviable tissue, is a crucial prerequisite for a wound to heal. […]

January 19, 2023 - 2 minutesmins - By Jim Cornall

circulating tumor cells, cancer, clinical trials

News and Trends 19 Jan 2023

Avacta completes fourth dose escalation in tumor study

Avacta Group plc says that AVA6000 continues to show a favorable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial. Additionally, analysis of tumor biopsies obtained from six patients across several cohorts indicates that doxorubicin is being released within the tumor tissue. This confirms the tumor targeting potential […]

January 19, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 19 Jan 2023

GPCR Therapeutics launches multiple myeloma trial

GPCR Therapeutics, Inc., a drug discovery company targeting G Protein Coupled Receptors (GPCR) pairs, has started its phase 2 trial in the U.S. for its lead small molecule asset, GPC-100. GPC-100 targets CXCR4, one of the most prevalent chemokine GPCRs overexpressed in more than 23 cancers. This randomized, open-label phase 2 study assesses the efficacy […]

January 19, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 19 Jan 2023

Pathalys Pharma brings in $150M for SHPT trials

Pathalys Pharma, Inc. and Launch Therapeutics (Launch Tx) have announced a collaboration to advance phase 3 clinical trials for upacicalcet (designated PLS240 for clinical trials) for the treatment of secondary hyperparathyroidism (SHPT) in patients on hemodialysis. Launch Therapeutics is backed by funds managed by global investment firm Carlyle and its life sciences franchise Abingworth. Pathalys […]

January 19, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Jan 2023

Ascletis phase I COVID trial progressing

Ascletis Pharma Inc. has announced the dosing of four healthy subjects in its multiple-dose escalation phase I clinical trial of oral 3-chymotrypsin like protease (3CLpro) inhibitor ASC11 in combination with 100 mg ritonavir tablets for COVID-19. The phase I clinical trial is expected to enroll 72 healthy subjects, including 60 subjects in single-dose escalation cohorts […]

January 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Jan 2023

EverImmune launches trial for oncobiotic lung and kidney cancer drug candidate

EverImmune, a clinical-stage biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, says the first patient has been treated in its phase I clinical trial (EV 2101) evaluating Oncobax AK in lung and kidney cancer patients. The aim of the trial is to assess the toxicity and efficacy […]

January 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 12 Jan 2023

Breast cancer most studied disease area in 2022

Phesi, a global provider of patient-centric data analytics, has released the results of its global analysis of all clinical trials conducted in 2022. The report, which analyzed 80,917 trial records, reveals that breast cancer retained its position as the most-studied disease area, followed by COVID-19. Three of the top five most-studied disease areas fell within oncology, […]

January 12, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 11 Jan 2023

Renexxion goes to FDA with cystic fibrosis drug

Renexxion Ireland Limited has opened an investigational new drug (IND) application with the U.S Food and Drug Administration (FDA) for naronapride for the treatment of GI motility disorders in patients with cystic fibrosis (CF). This is a first step towards conducting clinical trials of the drug candidate in CF patients. Naronapride, post approval, could be […]

January 11, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 11 Jan 2023

What the new year holds for clinical research

Catherine Gregor is the chief clinical trial officer at Florence Healthcare. The company’s clinical trial software is used in more than 12,000 research sites in 45 countries for management of documents, data, and workflows. We asked Gregor about the clinical trial technology landscape in 2023. Why is remote clinical research connectivity so important? Remote connectivity […]

January 11, 2023 - 6 minutesmins - By Jim Cornall

News and Trends 11 Jan 2023

Clinical trends for 2023

By Richard Staines, account director, Optimum Strategic Communications Few would deny that the decade has had a turbulent start, but after the tragedies of the COVID-19 pandemic and the Ukraine war, there’s hope that 2023 will see a new wave of clinical research. Exciting new technologies such as gene editing, gene therapy and a next […]

January 11, 2023 - 8 minutesmins - By External Contributor

News and Trends 9 Jan 2023

Selecta and Astellas sign LOPD treatment agreement

Selecta Biosciences, Inc. and Astellas Pharma Inc. have announced an exclusive licensing and development agreement for IdeXork (Xork). Xork is being studied as a potential next generation immunoglobulin G (IgG) protease that will be developed by Astellas for use with AT845, an investigational, adeno-associated virus (AAV)-based treatment for late-onset Pompe disease (LOPD) in adults. Pompe […]

January 9, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clinical trial

DeuterOncology closes financing round to start lung cancer study

Cloned maggot enzyme wound treatment moves closer to reality

Avacta completes fourth dose escalation in tumor study

GPCR Therapeutics launches multiple myeloma trial

Pathalys Pharma brings in $150M for SHPT trials

Ascletis phase I COVID trial progressing

EverImmune launches trial for oncobiotic lung and kidney cancer drug candidate

Breast cancer most studied disease area in 2022

Renexxion goes to FDA with cystic fibrosis drug

What the new year holds for clinical research

Clinical trends for 2023

Selecta and Astellas sign LOPD treatment agreement

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!